ArticlePLOS global public health2026
Trends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced HIV disease (AHD), treatment interruption and viraemia remain key challenges to effectiveness of HIV programmes in South Africa. Understanding the trends of these measures and their variation across geographic regions can inform more targeted and responsive interventions. We conducted a retrospective cohort study using routine, de-identified data from TIER.Net, a national HIV electronic register. We curated data from 116 primary care clinics in eThekwini, uMgungudlovu, and uMkhanyakude Districts in KwaZulu-Natal province. We included people living with HIV aged ≥16 years, who initiated or collected ART between 1 July 2018 and 30 June 2023. We examined trends in the annual clinic-level prevalence of AHD, treatment interruption and viraemia, and mapped these outcomes using inverse distance weighted interpolation restricted to 3 nearest neighbours to preserve local influence. Among 123,473 clients initiating ART with CD4 count measurements, the overall prevalence of AHD ranged between 20.0% and 22.2%. The prevalence of treatment interruptions ranged between 11.3% and 13.2% among the 544,066 clients who had scheduled visits. Of the 446,899 clients who had viral load results, overall viraemia, defined as ≥50 copies/mL, increased from 12.9% to 20.2%, whereas high-level viraemia defined as ≥1000 copies/mL remained stable at approximately 6%. Spatial analyses highlighted geographic disparities in AHD, treatment interruption, and viraemia across and within the districts. The persistence of AHD, treatment interruption and viraemia require further investigation and highlight ongoing challenges for HIV control. The observed spatial variation across and within districts spanning urban, peri-urban and rural settings highlight the need for geographically tailored interventions to improve programmatic effectiveness, particularly in hyper-endemic settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.